Showing 121 - 140 results of 150 for search '"Chiba University"', query time: 0.06s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132

    Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study by Mizoguchi Y, Hino M, Ueda H, Miyaguchi Y, Kobayashi M

    Published 2025-01-01
    “…Yoko Mizoguchi,1 Moeko Hino,2 Hitoshi Ueda,3 Yasuo Miyaguchi,3 Masao Kobayashi1,4 1Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; 2Department of Pediatrics, Chiba University Hospital, Chiba, Japan; 3Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 4Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, JapanCorrespondence: Yasuo Miyaguchi, Japan Medical Office, Takeda Pharmaceutical Company Limited, 2 Chome-1-1 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023, Japan, Tel +81 70-4921-7966, Email yasuo.miyaguchi1@takeda.comPurpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. …”
    Get full text
    Article
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140